性色在线视频,毛片h,日本五月天婷久久网站

▍最近瀏覽歷史

[清空]

▍更多產(chǎn)品

貨號：B245025
名稱：Acanthamoeba healyi Moura et al.

貨號：B245024
名稱：Saccharomyces cerevisiae Meyen ex E.C. Hansen

貨號：B245023
名稱：Saccharomyces cerevisiae Meyen ex E.C. Hansen

貨號：B245022
名稱：Eutypella vitis (Schweinitz) Cooke emend. Glawe

貨號：B245021
名稱：Streptomyces scabiei (Thaxter) Lambert and Loria

貨號：B245020
名稱：Graphium cuneiferum (Berkeley et Broome) Mason et Ellis

貨號：B245019
名稱：HFBCI28

貨號：B245018
名稱：Septoria passiflorae Sydow, anamorph

貨號：B245017
名稱：Dictyostelium purpureum Olive

貨號：B245016
名稱：Y71

▍聯(lián)系我們

0574-87157013
mingzhoubio@163.com
浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號
創(chuàng)e慧谷42號樓B幢401室

LS132.1D9 [1D9]

規(guī)格:

貨期:

編號:B209801

品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株

定量菌液

DNA

RNA

規(guī)格:

凍干粉

斜面

甘油

平板

加入購物車

在線咨詢收藏

產(chǎn)品名稱	LS132.1D9 [1D9]
商品貨號	B209801
Organism	Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type	hybridoma:
Product Format	frozen
Culture Properties	suspension
Biosafety Level	1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease	Lymphoma
Strain	Strain:? C57BL/6? (B cell); BALB/c? (myeloma)
Applications	The antibody binds to the human CC-chemokine receptor 2 (CCR2). Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region.
Storage Conditions	liquid nitrogen vapor phase
Disclosure	This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation	Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Comments	Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Complete Growth Medium	Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 25 mM HEPES, 20 pg/ml mouse recombinant Interleukin-6 (IL-6) and 20% fetal bovine serum
Subculturing	Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml. Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation	Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase
Culture Conditions	Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C
Isotype	IgG2a kappa
Name of Depositor	LeukoSite, Inc.
U.S. Patent Number	6,312,689
References	LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001 LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002 LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002 LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002 LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002 LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002 LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002 . Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002 LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002

序號	文章標(biāo)題	操作
1	ATCC細(xì)胞運(yùn)輸和處理	查看詳情
2	其他海外品牌代理	查看詳情
3	ATCC代理	查看詳情
4	購買須知	查看詳情
5	訂購流程	查看詳情

梅經(jīng)理	17280875617	1438578920
胡經(jīng)理	13345964880	2438244627
周經(jīng)理	17757487661	1296385441
于經(jīng)理	18067160830	2088210172
沈經(jīng)理	19548299266	2662369050
李經(jīng)理	13626845108	972239479